PUMA is a novel target of miR-221/222 in human epithelial cancers

International Journal of Oncology

Volumn 37, Issue 6, 2010, Pages 1621-1626

  Zhang, Chunzhi ^a,b,c   Zhang, Junxia ^a,b   Zhang, Anlin ^a,b   Wang, Yingyi ^d   Han, Lei ^b   You, Yongping ^d   Pu, Peiyu ^a,b   Kang, Chunsheng ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Department of Radiation Oncology   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Epithelial cancer; miR 221; miR 222; PUMA

Indexed keywords

CASPASE 3; CASPASE 7; MICRORNA; MICRORNA 221; MICRORNA 222; PUMA PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER CELL; CELL PROLIFERATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

3' UNTRANSLATED REGIONS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROTO-ONCOGENE PROTEINS; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 78649950629     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000816     Document Type: Article

References (23)

1. Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556-2568, 2005.
2. Spendlove I, Al-Attar A, Watherstone O, Webb TM, Ellis IO, Longmore GD and Sharp TV: Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival. Int J Cancer 123: 2247-2253, 2008.
3. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
4. Skaftnesmo KO, Prestegarden L, Micklem DR and Lorens JB: MicroRNAs in tumorigenesis. Curr Pharm Biotechnol 8: 320-325, 2007.
5. Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z and You Y: hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 1236: 185-193, 2008.
6. Zhang C, Han L, Zhang A, Yang W, Zhou X, Pu P, Du Y, Zeng H and Kang C: Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells. Int J Oncol 36: 1503-1512, 2010.
7. Zhang J, Han L, Ge Y, Zhou X, Zhang A, Zhang C, Zhong Y, You Y, Pu P and Kang C: miR-221/222 promote malignant progression of glioma through activation of the Akt pathway. Int J Oncol 36: 913-920, 2010.
8. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L and Negrini M: MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 15: 5073-5081, 2009.
9. Lu X, Zhao P, Zhang C, Fu Z, Chen Y, Lu A, Liu N, You Y, Pu P and Kang C: Analysis of miR-221 and p27 expression in human gliomas. Mol Med Rep 2: 651-656, 2009.
10. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG and Ciafre SA: The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 3: E4029, 2008.
11. Zhang C, Kang C, You Y, Pu P, Yang W, Zhao P, Wang G, Zhang A, Jia Z, Han L and Jiang H: Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol 34: 1653-1660, 2009.
12. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM and Condorelli G: MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27: 3845-3855, 2008. (Pubitemid 351862062)
13. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D and Cheng JQ: MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283: 31079-31086, 2008.
14. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G and Croce CM: miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 down-regulation. Cancer Cell 16: 498-509, 2009.
15. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S and Majumder S: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903, 2008.
16. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM and Huang DC: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403, 2005.
17. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD and Green DR: PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309: 1732-1735, 2005.
18. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T and Korsmeyer SJ: BCL-2, BCL-X(L) sequester BH3 domainonly molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711, 2001.
19. Zong WX, Lindsten T, Ross AJ, MacGregor GR and Thompson CB: BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 15: 1481-1486, 2001. (Pubitemid 32552527)
20. Yu J, Wang Z, Kinzler KW, Vogelstein B and Zhang L: PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100: 1931-1936, 2003.
21. Arnoult D: Apoptosis-associated mitochondrial outer membrane permeabilization assays. Methods 44: 229-234, 2008. (Pubitemid 351296439)
22. Yu J, Yue W, Wu B and Zhang L: PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res 12: 2928-2936, 2006. (Pubitemid 43752136)
23. Wang R, Wang X, Li B, Lin F, Dong K, Gao P and Zhang HZ: Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo. Breast Cancer Res Treat 117: 45-54, 2009.